Simplify Asset Management Inc. Acquires 944 Shares of argenx SE (NASDAQ:ARGX)

Simplify Asset Management Inc. lifted its stake in argenx SE (NASDAQ:ARGX - Free Report) by 64.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,419 shares of the company's stock after acquiring an additional 944 shares during the period. Simplify Asset Management Inc.'s holdings in argenx were worth $1,311,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. OneDigital Investment Advisors LLC grew its stake in shares of argenx by 13.2% in the third quarter. OneDigital Investment Advisors LLC now owns 1,194 shares of the company's stock worth $647,000 after acquiring an additional 139 shares during the last quarter. Oppenheimer & Co. Inc. acquired a new stake in argenx during the third quarter worth $453,000. Victory Capital Management Inc. boosted its stake in argenx by 69.8% during the third quarter. Victory Capital Management Inc. now owns 1,562 shares of the company's stock worth $847,000 after buying an additional 642 shares in the last quarter. Crossmark Global Holdings Inc. boosted its stake in argenx by 100.4% during the third quarter. Crossmark Global Holdings Inc. now owns 9,462 shares of the company's stock worth $5,130,000 after buying an additional 4,741 shares in the last quarter. Finally, TimesSquare Capital Management LLC boosted its stake in argenx by 8.8% during the third quarter. TimesSquare Capital Management LLC now owns 109,490 shares of the company's stock worth $59,352,000 after buying an additional 8,840 shares in the last quarter. Institutional investors and hedge funds own 60.32% of the company's stock.

argenx Stock Performance

Shares of NASDAQ ARGX traded down $30.81 during mid-day trading on Friday, reaching $564.23. The company had a trading volume of 591,504 shares, compared to its average volume of 309,100. argenx SE has a one year low of $327.73 and a one year high of $611.22. The firm has a market cap of $33.74 billion, a price-to-earnings ratio of -641.16 and a beta of 0.61. The business's 50-day simple moving average is $552.89 and its 200 day simple moving average is $481.22.

argenx (NASDAQ:ARGX - Get Free Report) last issued its quarterly earnings results on Thursday, October 31st. The company reported $1.39 EPS for the quarter, topping analysts' consensus estimates of $0.10 by $1.29. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The company had revenue of $588.88 million for the quarter, compared to analysts' expectations of $543.29 million. During the same quarter last year, the business earned ($1.25) earnings per share. On average, sell-side analysts anticipate that argenx SE will post 2.2 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on ARGX. JMP Securities lifted their price target on shares of argenx from $497.00 to $606.00 and gave the stock a "market outperform" rating in a research note on Friday, November 1st. JPMorgan Chase & Co. boosted their target price on shares of argenx from $640.00 to $670.00 and gave the company an "overweight" rating in a research note on Monday, November 4th. Piper Sandler lifted their price target on argenx from $553.00 to $620.00 and gave the company an "overweight" rating in a report on Friday, November 1st. Barclays raised argenx from an "equal weight" rating to an "overweight" rating in a report on Tuesday, August 6th. Finally, Wells Fargo & Company boosted their target price on argenx from $547.00 to $639.00 and gave the stock an "overweight" rating in a research report on Friday, November 1st. Three equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $619.79.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.